Synergistic inhibitory effects of cetuximab and curcumin on human cisplatin-resistant oral cancer CAR cells through intrinsic apoptotic process

Cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody (mAb), is a novel targeted therapy for the treatment of patients with oral cancer. Cetuximab can be used in combination with chemotherapeutic agents to prolong the overall survival rates of patients with oral cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chin-Fu, Lu, Chi-Cheng, Chiang, Jo-Hua, Chiu, Hong-Yi, Yang, Jai-Sing, Lee, Chao-Ying, Way, Tzong-Der, Huang, Hao-Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176463/
https://www.ncbi.nlm.nih.gov/pubmed/30333889
http://dx.doi.org/10.3892/ol.2018.9418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176463/
https://www.ncbi.nlm.nih.gov/pubmed/30333889
http://dx.doi.org/10.3892/ol.2018.9418

Ejemplares similares